Literature DB >> 22544471

Analysis of exposure-response of CI-945 in patients with epilepsy: application of novel mixed hidden Markov modeling methodology.

Maud Delattre1, Radojka M Savic, Raymond Miller, Mats O Karlsson, Marc Lavielle.   

Abstract

We propose to describe exposure-response relationship of an antiepileptic agent, using mixed hidden Markov modeling methodology, to reveal additional insights in the mode of the drug action which the novel approach offers. Daily seizure frequency data from six clinical studies including patients who received gabapentin were available for the analysis. In the model, seizure frequencies are governed by underlying unobserved disease activity states. Individual neighbouring states are dependent, like in reality and they exhibit their own dynamics with patients transitioning between low and high disease states, according to a set of transition probabilities. Our methodology enables estimation of unobserved disease dynamics and daily seizure frequencies in all disease states. Additional modes of drug action are achievable: gabapentin may influence both daily seizure frequencies and disease state dynamics. Gabapentin significantly reduced seizure frequencies in both disease activity states; however it did not significatively affect disease dynamics. Mixed hidden Markov modeling is able to mimic dynamics of seizure frequencies very well. It offers novel insights into understanding disease dynamics in epilepsy and gabapentin mode of action.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544471     DOI: 10.1007/s10928-012-9248-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  5 in total

1.  A hidden Markov model that finds genes in E. coli DNA.

Authors:  A Krogh; I S Mian; D Haussler
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971

2.  Dose-response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures.

Authors:  Eric Snoeck; Armel Stockis
Journal:  Epilepsy Res       Date:  2006-12-29       Impact factor: 3.045

3.  Qualitative longitudinal analysis of symptoms in patients with primary and metastatic brain tumours.

Authors:  Frank Rijmen; Edward H Ip; Stephen Rapp; Edward G Shaw
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2008       Impact factor: 2.483

4.  Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures.

Authors:  Raymond Miller; Bill Frame; Brian Corrigan; Paula Burger; Howard Bockbrader; Elizabeth Garofalo; Richard Lalonde
Journal:  Clin Pharmacol Ther       Date:  2003-06       Impact factor: 6.875

5.  Modelling overdispersion and Markovian features in count data.

Authors:  Iñaki F Trocóniz; Elodie L Plan; Raymond Miller; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-10-02       Impact factor: 2.745

  5 in total
  6 in total

1.  Pharmacometrics models with hidden Markovian dynamics.

Authors:  Marc Lavielle
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-08-31       Impact factor: 2.745

2.  A big data approach to the development of mixed-effects models for seizure count data.

Authors:  Joseph J Tharayil; Sharon Chiang; Robert Moss; John M Stern; William H Theodore; Daniel M Goldenholz
Journal:  Epilepsia       Date:  2017-03-30       Impact factor: 5.864

3.  Natural variability in seizure frequency: Implications for trials and placebo.

Authors:  Juan Romero; Phil Larimer; Bernard Chang; Shira R Goldenholz; Daniel M Goldenholz
Journal:  Epilepsy Res       Date:  2020-03-06       Impact factor: 3.045

4.  Modeling and simulation of count data.

Authors:  E L Plan
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-08-13

5.  Epilepsy as a dynamic disease: A Bayesian model for differentiating seizure risk from natural variability.

Authors:  Sharon Chiang; Marina Vannucci; Daniel M Goldenholz; Robert Moss; John M Stern
Journal:  Epilepsia Open       Date:  2018-04-20

6.  Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM.

Authors:  A Brekkan; S Jönsson; M O Karlsson; E L Plan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-10-26       Impact factor: 2.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.